← boardnext 2026-09
SLN
Silence Therapeutics plcdistress 4/10 · elevated risk$11.63-2%today-2% from 52w high
Lead: Polycythemia Vera
Revenue
pre-revenue
Liquidity
$70M
Runway
1.1 yrs
Shares 1y
0%
Price & events
+99.8% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.7%
1D
+6.5%
1W
+60.0%
1M
+48.3%
3M
+105.1%
6M
+89.1%
1Y
-46.5%
2Y
-53.5%
5Y
-51.5%
All
Overview
- Market Cap
- $1.65B
- Volume
- 43.01K
- 52 Week Range
- $4.30 – $11.83
- Total Shares
- 141.70M
- Float Shares
- 27.46M
- Short %
- 4.86%
- % Held by Insiders
- 21.77%
- % Held by Institutions
- 44.57%
- RVOL
- 0.08x
- Beta
- 1.38
Pipeline stages · 1 programs
SLN124
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-09 Estimated 50% readout ~2026-10-16 | Phase 1/2 | SLN124 | Polycythemia Vera | — | active not recruiting |
Catalyst news & presentations · 1
- 2026-08-06earningsEarningsEarnings releaseyahoo
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: 141,703,840 · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $29 (+151% upside) · 6 analysts
- 2026-06-24Cantor FitzgeraldOverweight
- 2026-06-17HC Wainwright & Co.Buy
- 2026-03-13HC Wainwright & Co.Buy
- 2025-09-16HC Wainwright & Co.Buy
- 2025-08-08Chardan CapitalBuy
- 2025-06-13Chardan CapitalBuy
Competitors — Polycythemia Vera
- MRKMerck & Co., Inc.$318.8B · D3
- GSKGSK plc$217.0B · D1
- TKPHFTAKEDA PHARMACEUTICAL CO LTD$53.7B · D1
- INCYINCYTE CORP$23.1B · D0
- IONSIONIS PHARMACEUTICALS INC$9.2B · D2
- PTGXProtagonist Therapeutics, Inc$8.6B · D0
- IRONDisc Medicine, Inc.$2.8B · D1
- AGIOAGIOS PHARMACEUTICALS, INC.$2.1B · D5
- PRLDPrelude Therapeutics Inc$307M · D6
- SLNCFSilence Therapeutics plc$213M · D5
Recent news
- 2026-07-19SLN stock skyrockets 107% in six months: Here's what you need to know - MSN
- 2026-07-16ETFs Investing in Silence Therapeutics PLC Sponsored ADR Stocks - TradingView
- 2026-07-16SLN Stock Skyrockets 107% in Six Months: Here's What You Need to Know - Yahoo Finance UK
- 2026-07-16Silence Therapeutics (SLN) Moves 7.2% Higher: Will This Strength Last? - Yahoo Finance Singapore
- 2026-07-12Silence Therapeutics: PV Data Could Wake The Stock (Initiating Buy) (NASDAQ:SLN) - Seeking Alpha
- 2026-07-08Richard Griffiths updates Silence Therapeutics (SLN) holdings in latest 13D/A - Stock Titan
- 2026-07-02Silence Therapeutics (SLN) Gains 3.24% as Price Tests Key Resistance Level - Volatility Stop - dars.gov.et
- 2026-06-26Enterprise value to EBIT forward of Silence Therapeutics Plc - American Depository Share – NASDAQ:SLN - TradingView
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.